Abbott Laboratories vs Upwork Inc — how do they compare? Abbott Laboratories trades at $110.97 (market cap $187.95B), while Upwork Inc trades at $8.31 (market cap $1.04B). The key difference: Abbott Laboratories is far larger — about 180.7× Upwork Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| ABT | UPWK | |
|---|---|---|
Market Cap | $187.95B | $1.04B |
Sector | Health | Industrials |
52-Week High | $136.62 | $22.11 |
52-Week Low | $82.57 | $7.84 |
Enterprise Value | $214.96B | $806.15M |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
UPWK is trading at $8.25, down 16.12% amid weak guidance overshadowing a recent Q2 earnings beat. The stock shows bearish technical signals with key support at $8.00. Fundamentally, revenue grew to $787.78M in 2025 with a net income margin of 12.93%, though earnings have been mixed with three misses in the last four quarters. Recent news highlights concerns over declining active clients and AI-driven market shifts.
The outlook is cautious; while valuation ratios like P/E of 10.71 appear reasonable, near-term risks from competitive pressures and investor lawsuits pose headwinds. Analyst consensus is a Buy with a $9.25 target, suggesting potential upside if execution improves, but sentiment remains fragile post-earnings.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →